Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 clinical study to investigate the safety, pharmacokinetics and
pharmacodynamics of AB-16B5 in patients with an advanced solid malignancy. AB-16B5 is a
humanized monoclonal antibody that inhibits the activity of the secreted form of clusterin
(sCLU), a potent inducer of the epithelial-to-mesenchymal transition (EMT). Eligible subjects
will have a disease that has been refractory to prior therapy and is unlikely to benefit from
known therapies.